Company news
Voyageur Pharmaceuticals Ltd news in 2026
Voyageur Pharmaceuticals Ltd's news releases, calls and decks from 2026, newest first.
Voyageur Pharmaceuticals Announces Completion of Shares for Debt Settlement
October 2, 2026
Voyageur Pharmaceuticals Announces Proposed Issuance of Shares for Debt
September 24, 2026
(PODCAST) Voyageur Pharmaceuticals (TSXV: VM) Achieves First Milestone in Bayer Collaboration, Secures USD $1 Million Payment
September 10, 2026
Voyageur Pharmaceuticals Achieves First Milestone on Feasibility Study for Iodine Production; Secures USD $1 Million Payment
September 9, 2026
Voyageur Pharmaceuticals Advances Mueller Iodine Extraction Process With 99.8% Purity Results and Planned Field Pilot Testing
August 10, 2026
Voyageur Pharmaceuticals Announces the Engagement of Red Cloud Securities as Market Maker
July 17, 2026
Voyageur Pharmaceuticals Engages Fluor to Advance Feasibility Studies for Iodine Production and Integrated Contrast Drug Manufacturing Facility
June 23, 2026
Voyageur Pharmaceuticals Evaluating Three Locations in the United States for Integrated Iodine and Barium Contrast Media Manufacturing Facility, a Multi-Phase Investment Expected to Generate Significant Economic Impact and High-Skilled Jobs; Competitive Site Selection Process Underway
June 18, 2026
Voyageur Pharmaceuticals Ltd. Submits Multi-Year Area-Based Exploration Permit Application for Bulk Sampling and Feasibility Support at Frances Creek Barite Project
June 10, 2026
Voyageur Announces Closing Of Non-Brokered Private Placement Pursuant To Listed Issuer Financing Exemption
June 5, 2026
Voyageur Announces Filing Of Amended And Restated Offering Document
May 28, 2026
Voyageur Announces Update To Non-Brokered Life Offering
May 1, 2026
Voyageur Announces Shares for Debt Settlement and Stock Option Repricing
April 17, 2026
Voyageur Announces Non-Brokered Life Offering
March 25, 2026
Voyageur Announces Advancements on its Barium & Iodine Contrast Media Projects
March 16, 2026
Voyageur Pharmaceuticals Confirms Pharmaceutical-Grade Purity of Barite from Frances Creek and Progresses to Health Canada Human Trial with Alberta Innovates Grant
March 5, 2026
Voyageur Pharmaceuticals Confirms Pharmaceutical-Grade Purity of Barite from Frances Creek and Progresses to Health Canada Human Trial With Alberta Innovates Grant; Announces Stock Option and DSU Grants, and Proposed Issuance of Securities for Debt
March 4, 2026
Voyageur Pharmaceuticals Confirms Pharmaceutical-Grade Purity of Barite from Frances Creek and Progresses to Health Canada Human Trial with Alberta Innovates Grant; Announces Stock Option and DSU grants, and Proposed Issuance of Securities for Debt
March 4, 2026
Voyageur Pharmaceuticals Announces Collaboration With Bayer
February 23, 2026
Voyageur Pharmaceuticals Announces Collaboration with Bayer
February 23, 2026
Voyageur Pharmaceuticals Strengthens Scientific Team by Adding Dr. Brian Mueller as Director of Chemistry and Secures Exclusive Ownership of Iodine Extraction Technology
January 12, 2026